Join the Riabni group to help and get support from people like you.
Riabni News
Rituximab Not Superior to Conventional Strategy for Eosinophilic Granulomatosis With Polyangiitis
FRIDAY, Aug. 1, 2025 – For patients with eosinophilic granulomatosis with polyangiitis (EGPA), rituximab is not superior to the conventional remission induction strategy, according to a study...
Anti-CD20 Therapy Shows No Effect on Disability Progression in MS
THURSDAY, Sept. 26, 2024 – For patients with primary progressive multiple sclerosis (PPMS), the time to confirmed disability progression (CDP) does not differ for those who are anti-CD20-treated and...
FDA Approves Riabni (rituximab-arrx), a Biosimilar to Rituxan (rituximab), for Adults with Moderate to Severe Rheumatoid Arthritis
THOUSAND OAKS, Calif., June 6, 2022 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Riabni (rituximab-arrx), a biosimilar to...
FDA Approves Riabni (rituximab-arrx), a Biosimilar to Rituxan
THOUSAND OAKS, Calif., Dec. 17, 2020 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Riabni (rituximab-arrx), a biosimilar to...
Further information
Related condition support groups
Non-Hodgkin's Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis